Objective: To evaluate whether botulinum toxin type A injections improve upper limb function in children with cerebral palsy.
Methods: An extensive search was carried out in PUBMED, CINAHL, PICARTA, EMBASE, PEDRO and the Cochrane Controlled Trials Register. Controlled and uncontrolled studies were included and evaluated on the basis of a best evidence synthesis.
Results: Twelve out of 645 identified studies were included: three randomized controlled trials (RCTs) (n = 64) of high methodological quality, and nine uncontrolled studies (n = 107) of sufficient methodological quality. In one of the three RCTs a short-term, significant decrease of spasticity was found in favour of the botulinum toxin type A group, which was supported by five of the seven uncontrolled studies that also measured spasticity. In one RCT significant changes in range of motion were reported for wrist and thumb extension. This finding was supported by two out of seven uncontrolled studies. One RCT reported a significant improvement in activities after one month, according to the Quality of Upper Extremity Skills Test and the Pediatric Evaluation Disability Inventory, whereas five out of the nine uncontrolled studies reported an improvement in functional activities.
Conclusion: Insufficient evidence is found for the effects of botulinum toxin type A injections to reduce spasticity or to increase range of motion and upper limb function in children with cerebral palsy. Besides differences in treatment goals, the lack of evidence is mainly due to the use of invalid assessment instruments and insufficient statistical power to demonstrate treatment effects.
Get full access to this article
View all access options for this article.
References
1.
1 Bax M, Goldstein M, Rosenbaum P et al. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol2005; 47: 571-576.
2.
2 Surveillance of Cerebral Palsy in Europe (SCPE). Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol2000; 42: 816-824.
3.
3 Hagberg B, Hagberg G, Beckung E, Uvebrant P. Changing panorama of cerebral palsy in Sweden. VIII. Prevalence and origin in the birth year period 1991-94. Acta Paediatr2001; 90: 271-277.
5 Boyd RN, Morris ME, Graham HK. Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol2001; 8(suppl 5): 150-166.
6.
6 Wasiak J, Hoare B, Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev2004; 4: CD003469.
7.
7 Van Tulder MW, Assendelft WJ, Koes BW, Bouter LM. Method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine1997; 22: 2323-2330.
8.
8 World Health Organization. International classification of functioning, disability and health. World Health Organization, 2001.
9.
9 Steultjens EM, Dekker J, Bouter LM, van de Nes JC, Lambregts BL, van den Ende CH. Occupational therapy for children with cerebral palsy: a systematic review. Clin Rehabil2004; 18: 1-14.
10.
10 Van Tulder MW, Cherkin DC, Berman B, Lao L, Koes BW. Acupuncture for low back pain. Cochrane Database Syst Rev2000; 2: CD001351.
11.
11 Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr2000; 137: 331-337.
12.
12 Fehlings D, Rang M, Glazier J, Steele C. Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome. Eur J Neurol2001; 8(suppl 5): 145-149.
13.
13 Autti-Rämö I, Larsen A, Peltonen J, Taimo A, von Wendt L. Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia. Neuropediatrics2000; 31: 4-8.
14.
14 Autti-Rämö I, Larsen A, Taimo A, von Wendt L. Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. Eur J Neurol2001; 8(suppl 5): 136-144.
15.
15 Chin TY, Graham HK. Botulinum toxin A in the management of upper limb spasticity in cerebral palsy. Hand Clin2003; 19: 591-600.
16.
16 Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol1997; 39: 185-193.
17.
17 Zancolli EA, Zancolli E Jr. Surgical rehabilitation of the spastic upper limb in cerebral palsy. In Lamb DW ed. The paralyzed hand. Churchill Livingstone, 2005: 153-160.
18.
18 Speth LA, Leffers P, Janssen-Potten YJ, Vles JS. Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol2005; 47: 468-473.
19.
19 Denislic M, Meh D. Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics1995; 26: 249-252.
20.
20 Friedman A, Diamond M, Johnston MV, Daffner C. Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehabil2000; 79: 53-59.
21.
21 Hurvitz EA, Conti GE, Brown SH. Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection. Arch Phys Med Rehabil2003; 84: 444-454.
22.
22 Hurvitz EA, Conti GE, Flansburg EL, Brown SH. Motor control testing of upper limb function after botulinum toxin injection: a case study. Arch Phys Med Rehabil2000; 81: 1408-1415.
23.
23 Wallen MA, O'flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil2004; 85: 192-200.
24.
24 Wong V, Ng A, Sit P. Open-label study of botulinum toxin for upper limb spasticity in cerebral palsy. J Child Neurol2002; 17: 138-142.
25.
25 Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil2003; 82: 284-289.
26.
26 Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner1964; 192: 540-542.
27.
27 Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther1987; 67: 206-207.
28.
28 Walsh E.G. Assessment of human hemiplegic spasticity by a resonant frequency method. Clin Biomech2005; 3: 173-178.
29.
29 Tardieu G, Shentoub S, Delarue R. Research on a technic for measurement of spasticity. Rev Neurol (Paris)1954; 91: 143-144.
30.
30 Wall SA, Chait LA, Temlett JA, Perkins B, Hillen G, Becker P. Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg1993; 46: 703-706.
31.
31 Norkin CC, White DJ. Measurement of joint motion: a guide to goniometry. FA Davis, 1985.
32.
32 DeMatteo C, Law M, Russell D, Pollock N, Rosenbaum P, Walter S. The reliability and validity of the Quality of Upper Extremity Skills Test. Phys Occup Ther Pediatr1993; 13: 1-18.
33.
33 Randall M, Carlin JB, Chondros P, Reddihough D. Reliability of the Melbourne assessment of unilateral upper limb function. Dev Med Child Neurol2001; 43: 761-767.
34.
34 Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med1991; 324: 1186-1194.
35.
35 Spasticity: disordered motor control. Year Book Medical Publishers, 1980.
36.
36 McDowell BC, Hewitt V, Nurse A, Weston T, Baker R. The variability of goniometric measurements in ambulatory children with spastic cerebral palsy. Gait Posture2000; 12: 114-121.
37.
37 Gormley ME, Jr, O'Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spasticity. Muscle Nerve Suppl1997; 6: S14-S20.
